Xu Shengshan相关文献与解析，生知库 | 链接生命科学的每一步

Antibody-drug conjugates as immuno-oncology agents in colorectal cancer: targets, payloads, and therapeutic synergies

抗体药物偶联物作为结直肠癌免疫肿瘤治疗药物：靶点、有效载荷和治疗协同作用

期刊:Frontiers in Immunology

影响因子:5.9

doi:10.3389/fimmu.2025.1678907

Wang, Yihan; Lu, Kai; Xu, Yang; Xu, Shengshan; Chu, Hongyu; Fang, Xuedong

The Role of PLIN3 in Prognosis and Tumor-Associated Macrophage Infiltration: A Pan-Cancer Analysis.

PLIN3 在预后和肿瘤相关巨噬细胞浸润中的作用：泛癌分析

期刊:Journal of Inflammation Research

影响因子:4.1

doi:10.2147/JIR.S509245

Yang Shaohua, Liu Hejie, Zheng Youbin, Chu Hongyu, Lu Zhuming, Yuan Jie, Xu Shengshan

Interplay of disulfidptosis and the tumor microenvironment across cancers: implications for prognosis and therapeutic responses.

二硫键凋亡与肿瘤微环境在癌症中的相互作用：对预后和治疗反应的影响

期刊:BMC Cancer

影响因子:3.4

doi:10.1186/s12885-025-14246-1

Xu Shengshan, Chen Zizhou, Chen Xiguang, Chu Hongyu, Huang Xufeng, Chen Chunyu, Liu Hejie, Qu Yuting, Lu Zhuming

Discovery of PAK2 as a Key Regulator of Cancer Stem Cell in Head and Neck Squamous Cell Carcinoma Using Multi-Omic Techniques

利用多组学技术发现PAK2是头颈部鳞状细胞癌中癌症干细胞的关键调控因子

期刊:Stem Cells International

影响因子:3.3

doi:10.1155/sci/1325262

Wang, Puyu; Xu, Shengshan; Guo, Qian; Zhao, Yulin

Targeting T cell exhaustion: emerging strategies in non-small cell lung cancer

靶向T细胞耗竭：非小细胞肺癌的新兴策略

期刊:Frontiers in Immunology

影响因子:5.9

doi:10.3389/fimmu.2024.1507501

Liu, Xianqiang; Xi, Xiaowei; Xu, Shengshan; Chu, Hongyu; Hu, Penghui; Li, Dong; Zhang, Bin; Liu, Hejie; Jiang, Tianxiao; Lu, Zhuming

Causal association between immune cells and lung cancer risk: a two-sample bidirectional Mendelian randomization analysis

免疫细胞与肺癌风险之间的因果关系：一项双样本双向孟德尔随机化分析

期刊:Frontiers in Immunology

影响因子:5.9

doi:10.3389/fimmu.2024.1433299

Xu, Shengshan; Fang, Huiying; Shen, Tao; Zhou, Yufu; Zhang, Dongxi; Ke, Yongwen; Chen, Zhuowen; Lu, Zhuming

Comprehensive pan-cancer analysis reveals EPHB2 is a novel predictive biomarker for prognosis and immunotherapy response

全面的泛癌分析表明，EPHB2 是一种新型的预测性生物标志物，可用于预测预后和免疫治疗反应。

期刊:BMC Cancer

影响因子:3.4

doi:10.1186/s12885-024-12843-0

Xu, Shengshan; Zheng, Youbin; Ye, Min; Shen, Tao; Zhang, Dongxi; Li, Zumei; Lu, Zhuming

Multiâomics identification of a signature based on malignant cell-associated ligand-receptor genes for lung adenocarcinoma.

基于恶性细胞相关配体受体基因的多组学鉴定肺腺癌特征

期刊:BMC Cancer

影响因子:3.4

doi:10.1186/s12885-024-12911-5

Xu Shengshan, Chen Xiguang, Ying Haoxuan, Chen Jiarong, Ye Min, Lin Zhichao, Zhang Xin, Shen Tao, Li Zumei, Zheng Youbin, Zhang Dongxi, Ke Yongwen, Chen Zhuowen, Lu Zhuming

A Novel Signature Integrated of Immunoglobulin, Glycosylation and Anti-Viral Genes to Predict Prognosis for Breast Cancer

一种整合免疫球蛋白、糖基化和抗病毒基因的新型特征可用于预测乳腺癌预后

期刊:Frontiers in Genetics

影响因子:2.8

doi:10.3389/fgene.2022.834731

Xu, Shengshan; Liu, Yuchen; Ma, Hansu; Fang, Shuo; Wei, Shoupeng; Li, Xiaoping; Lu, Zhuming; Zheng, Youbin; Liu, Tong; Zhu, Xiaojian; Xu, Dongming; Pan, Yihang

JAK inhibition in PD-1 immunotherapy and tumor microenvironment

PD-1免疫疗法中的JAK抑制及肿瘤微环境

Antibody-drug conjugates as immuno-oncology agents in colorectal cancer: targets, payloads, and therapeutic synergies

抗体药物偶联物作为结直肠癌免疫肿瘤治疗药物：靶点、有效载荷和治疗协同作用

The Role of PLIN3 in Prognosis and Tumor-Associated Macrophage Infiltration: A Pan-Cancer Analysis.

PLIN3 在预后和肿瘤相关巨噬细胞浸润中的作用：泛癌分析

Interplay of disulfidptosis and the tumor microenvironment across cancers: implications for prognosis and therapeutic responses.

二硫键凋亡与肿瘤微环境在癌症中的相互作用：对预后和治疗反应的影响

Discovery of PAK2 as a Key Regulator of Cancer Stem Cell in Head and Neck Squamous Cell Carcinoma Using Multi-Omic Techniques

利用多组学技术发现PAK2是头颈部鳞状细胞癌中癌症干细胞的关键调控因子

Targeting T cell exhaustion: emerging strategies in non-small cell lung cancer

靶向T细胞耗竭：非小细胞肺癌的新兴策略

Causal association between immune cells and lung cancer risk: a two-sample bidirectional Mendelian randomization analysis

免疫细胞与肺癌风险之间的因果关系：一项双样本双向孟德尔随机化分析

Comprehensive pan-cancer analysis reveals EPHB2 is a novel predictive biomarker for prognosis and immunotherapy response

全面的泛癌分析表明，EPHB2 是一种新型的预测性生物标志物，可用于预测预后和免疫治疗反应。

Multiâomics identification of a signature based on malignant cell-associated ligand-receptor genes for lung adenocarcinoma.

基于恶性细胞相关配体受体基因的多组学鉴定肺腺癌特征

A Novel Signature Integrated of Immunoglobulin, Glycosylation and Anti-Viral Genes to Predict Prognosis for Breast Cancer

一种整合免疫球蛋白、糖基化和抗病毒基因的新型特征可用于预测乳腺癌预后

JAK inhibition in PD-1 immunotherapy and tumor microenvironment

PD-1免疫疗法中的JAK抑制及肿瘤微环境

Antibody-drug conjugates as immuno-oncology agents in colorectal cancer: targets, payloads, and therapeutic synergies

抗体药物偶联物作为结直肠癌免疫肿瘤治疗药物：靶点、有效载荷和治疗协同作用

The Role of PLIN3 in Prognosis and Tumor-Associated Macrophage Infiltration: A Pan-Cancer Analysis.

PLIN3 在预后和肿瘤相关巨噬细胞浸润中的作用：泛癌分析

Interplay of disulfidptosis and the tumor microenvironment across cancers: implications for prognosis and therapeutic responses.

二硫键凋亡与肿瘤微环境在癌症中的相互作用：对预后和治疗反应的影响

Discovery of PAK2 as a Key Regulator of Cancer Stem Cell in Head and Neck Squamous Cell Carcinoma Using Multi-Omic Techniques

利用多组学技术发现PAK2是头颈部鳞状细胞癌中癌症干细胞的关键调控因子

Targeting T cell exhaustion: emerging strategies in non-small cell lung cancer

靶向T细胞耗竭：非小细胞肺癌的新兴策略

Causal association between immune cells and lung cancer risk: a two-sample bidirectional Mendelian randomization analysis

免疫细胞与肺癌风险之间的因果关系：一项双样本双向孟德尔随机化分析

Comprehensive pan-cancer analysis reveals EPHB2 is a novel predictive biomarker for prognosis and immunotherapy response

全面的泛癌分析表明，EPHB2 是一种新型的预测性生物标志物，可用于预测预后和免疫治疗反应。

Multiâomics identification of a signature based on malignant cell-associated ligand-receptor genes for lung adenocarcinoma.

基于恶性细胞相关配体受体基因的多组学鉴定肺腺癌特征

A Novel Signature Integrated of Immunoglobulin, Glycosylation and Anti-Viral Genes to Predict Prognosis for Breast Cancer

一种整合免疫球蛋白、糖基化和抗病毒基因的新型特征可用于预测乳腺癌预后

Multiâomics identification of a signature based on malignant cell-associated ligand-receptor genes for lung adenocarcinoma.